Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Session 3 - Quantitative Liquid-biopsy Biomarkers as Clinical Trials End Point

Role of cfDNA in Monitoring Response and Relapse: the Example of Liquid Biopsy Minimal Residual Disease as Clinical Trial Endpoint

Date

15 Jun 2021

Session

Session 3 - Quantitative Liquid-biopsy Biomarkers as Clinical Trials End Point

Presenters

V. Morris, US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings